Home Compare GSK.L vs JNJ
Stock Comparison · Industry comparison · Drug Manufacturers - General

GSK vs Johnson & Johnson: Which Stock Looks Stronger in 2026?

GSK holds the cleaner structural position, with the lead spread across valuation and profitability. Johnson & Johnson still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (GSK.L: STOXX 600, JNJ: Russell 1000).

Updated 2026-05-17

This is not just a one-metric split: both valuation and profitability materially support the lead. GSK plc leads by 9 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GSK.L and JNJ share the same industry classification.

For a similarity-based comparison, see how GSK and Johnson & Johnson each position within their functional peer groups in AssetNext.

Peer-Relative Score
GSK.L
GSK plc
67
Peer-Score
Signal qualityMedium
Peer basis: STOXX 600
vs
JNJ
Johnson & Johnson
58
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: GSK.L vs JNJ Profitability 68 52 Stability 76 90 Valuation 84 64 Growth 30 28 GSK.L JNJ
Gap Ranking
#1 Valuation +20
#2 Profitability +16
#3 Stability +14
#4 Growth +2
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and JNJ Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LJNJ Relative valuation Structural strength

The two profiles are relatively close, but the price setup still leans toward GSK plc.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but GSK plc still holds a clear edge.
Profitability
On profitability, the edge still sits with GSK plc, even though both profiles look solid.
Valuation — Dominant Gap
GSK.L
84
JNJ
64
Gap+20in favour of GSK.L

The multiple-based pricing edge comes from a forward P/E that is 8.3 turns lower.

What keeps the gap from being one-sided

Stability still leans toward Johnson & Johnson, so the lead is real without reading as one-way.

What this means for the comparison

The lead is built on both valuation and profitability — though stability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the GSK.L vs JNJ comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-profitability comparisons

Explore how GSK.L and JNJ each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.